Australia markets open in 7 hours 49 minutes

Cellectis S.A. (CMVLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
2.46000.0000 (0.00%)
As of 01:48PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close2.4600
Open2.4600
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.4600 - 2.4600
52-week range1.9300 - 6.2400
Volume100
Avg. volume255
Market cap112.092M
Beta (5Y monthly)2.00
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Cellectis Announces Closing of Global Offering and Exercise of Underwriters’ Option to Purchase Additional Shares

    NEW YORK, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today: the initial closing on February 7, 2023 of the previously announced underwritten global offering by way of a capital increase of 8,800,000 American Depositary Shares (the “ADSs”), each representing the right to receive one

  • GlobeNewswire

    Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information

    NEW YORK, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, in accordance with French regulatory requirements, is supplementing its previous announcement of the pricing of its underwritten global offering by way of a capital increase of 8,800,000 American Depositary Shares (“ADS”), each representin

  • GlobeNewswire

    Cellectis Announces Pricing of Follow-On Offering

    NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (“Cellectis” or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announces the pricing of its previously announced underwritten global offering by way of a capital increase of 8,800,000 American Depositary Shares (“ADS”), each representing the right to receive one ordinary share of Cellectis, nominal va